Recent Updates
Recently added Catalysts
BMRN Positive Sentiment Score: 75/100

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be...

Key Takeaway: BioMarin Pharmaceutical Inc. is hosting its Investor Day today at 10:30 a.m. Eastern Time in New York, which can be accessed virtually. The event will include presentations from the leadership team, focusing on the company's strategic priorities aimed at delivering significant value creation. A question-and-answer session is also planned following the presentations. BioMarin is recognized for its commitment to innovative therapies addressing rare genetic disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin highlights a commitment to value creation.
  • Investor Day showcases strong leadership and strategic priorities.
  • The company has successfully developed eight therapies for rare genetic disorders.

Full Press Release Details

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here .
Led by President and Chief Executive Officer Alexander Hardy , the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore BioMarin's commitment to deliver significant value creation. A question-and-answer session will follow prepared remarks.
BioMarin's Investor Day Agenda:
A link to the live webcast, replay and presentation slides will be available on BioMarin's Investor Relations website for at least 12 months at investors.biomarin.com .
About BioMarin Founded in 1997, BioMarin is a global biotechnology Company dedicated to transforming lives through genetic discovery. The Company develops and commercializes targeted therapies that address the root cause of genetic conditions. BioMarin's unparalleled research and development capabilities have resulted in eight transformational commercial therapies for patients with rare genetic disorders. The Company's distinctive approach to drug discovery has produced a diverse pipeline of commercial, clinical, and pre-clinical candidates that address a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a substantial benefit over existing treatment options. For additional information, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (415) 218-7111
SOURCE BioMarin Pharmaceutical Inc.

21 %

Frequently Asked Questions

When is BioMarin's Investor Day event?

BioMarin's Investor Day is on September 4, 2024, at 10:30 a.m. ET.

Who will lead the Investor Day presentations?

The presentations will be led by President and CEO Alexander Hardy.

How can I access the Investor Day event?

The event can be accessed virtually through a link available online.

What type of company is BioMarin?

BioMarin is a biotechnology company focused on genetic discovery and therapies.

How long will the web presentation be available?

The webcast and presentation will be available for at least 12 months.

Last updated: Sep 4, 2024